The FDA granted tentative approval for Avadel's Lumryz to treat excessive daytime sleepiness [EDS] or cataplexy in adults with narcolepsy. Jazz (JAZZ) which markets Xyrem for the same indication ...

"Kevin’s expertise and proven track record in building and leading specialized sales teams will be invaluable as we continue building momentum behind the launch of LUMRYZ, our FDA-approved ...

Our ownership predates most of the directors on the current Board. We have been big believers in Lumryz, a drug that the FDA has found on numerous occasions to be clinically superior to all other ...

Corporate and Pipeline Updates: Received FDA approval for LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness (EDS) in pediatric patients 7 years of age and older with narcolepsy.